Studies how diabetes medicines affect heart and blood vessel function
Observes heart and blood vessel changes in adults with type 2 diabetes on different medicines.
Plain-language title generated from the registry record
Registry title: The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination
Key facts
- Where
- Athens, GreeceSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 45 and 80 years old?
Source: NCT03878706, who can take part
Where in Greece
- Attikon University General HospitalAthens, GreeceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Athens
- Trial code
- NCT03878706
- Record updated
- 13 March 2026
- Original description
A. Four groups of patients with type 2 diabetes mellitus with high or very high cardiovascular risk or heart failure with preserved ejection fraction (HFpEF) will be studied before and at 6 and 12 months of treatment:Read full original descriptionShow less
The Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination on Endothelial Function, Arterial Stiffness and Left Ventricular Deformation in Patients With Type 2 Diabetes With High Cardiovascular Risk
A. Four groups of patients with type 2 diabetes mellitus with high or very high cardiovascular risk or heart failure with preserved ejection fraction (HFpEF) will be studied before and at 6 and 12 months of treatment:
* 60 patients treated with a combination of GLP1 analogue and SGLT2 inhibitor ± metformin * 60 patients treated with GLP-1 agonist as a second step after metformin * 60 patients treated with SGLT2 inhibitor as a second step after metformin * 60 patients treated with a combination of insulin and other antidiabetic agents (metformin - DPP4 inhibitors) Individuals will be equal distributed as far as age, gender and body mass index concerned. In addition, patients suffered from kidney disease and retinopathy are excluded.
Inclusion: Subject has type 2 diabetes mellitus; Subject has high or very high cardiovascular risk; Subject has heart failure with preserved ejection fraction.
Exclusion: Subject has type 1 diabetes mellitus; Subject has kidney disease; Subject has retinopathy.